CN1579515A - Medicine for treating hysteromyoma and its preparation method - Google Patents
Medicine for treating hysteromyoma and its preparation method Download PDFInfo
- Publication number
- CN1579515A CN1579515A CN 200410027218 CN200410027218A CN1579515A CN 1579515 A CN1579515 A CN 1579515A CN 200410027218 CN200410027218 CN 200410027218 CN 200410027218 A CN200410027218 A CN 200410027218A CN 1579515 A CN1579515 A CN 1579515A
- Authority
- CN
- China
- Prior art keywords
- medicine
- sargassum
- hysteromyoma
- capsule
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine for curing hysteromyoma. It uses alga, burred tuber, duchesnea, Chinese sage, liquorice, barbat skullcap, bistort, co donopsis pilosula root as materials. Through extraction, condensing, drying and crash the materials can be produced into extractive powder, then adds in accessories and produces the capsule. The medicine in the invention has functions of pathogen dispersing, stimulating circulation to end stasis, supporting the healthy energy. It can be applied to hysteromyoma, the symptom is the menstrual period is prolongs, and the quantity is overmuch, and so on. The medicine has an excellent effect and it has no toxin and side effects.
Description
Affiliated technical field
The present invention relates to a kind of medicine for the treatment of hysteromyoma, being specifically related to a kind of is the Chinese patent medicine of feedstock production with the Chinese herbal medicine, the invention still further relates to the preparation method of this medicine.
Background technology
Hysteromyoma is made up of smooth muscle and connective tissue, claim leiomyoma of uterus again, it is one of modal benign tumor in the female sex organs, period of duration women sickness rate is about 25%, be common in 30-50 year age level, especially the highest with 40-50 year sickness rate, account for 50-60%, sickness rate is in rising trend in recent years.Hysteromyoma is divided into intramural myoma, accounts for total 55-70%; Subserous myoma accounts for total 20-30%; Fleshy polyp accounts for total 10-15%.Hysteromyoma can cause hyper-menorrhea, menostaxis, cycle shortening, irregular vagina bleeding, leucorrhoea grow in quantity, anemia etc., even causes infertilely, and tumor increases the compressing bladder can cause diseases such as frequent micturition, dysuria and constipation.Have a strong impact on women's physical and mental health and routine work life,, also might be converted into malignant tumor if treatment is untimely.
The method of treatment hysteromyoma has at present: (1) hormonotherapy: though the method can effectively be treated hysteromyoma, can destroy patient's incretion balance, cause variations such as femaleness, easily cause other disease, thereby be very limited.(2) radiation therapy: adopt and place radioactive source in deep X ray illumination or the uterine cavity, this kind method easily makes the patient produce toxicity, destroys people's homoiostasis, reduces body immunity.(3) operative therapy: two kinds of the uterus extraction method of withing a hook at the end and uterectomys, the patient suffering is big, and wound healing time is long, part or all of afunction, and the relapse rate of hysterectomy method is higher, the treatment that need undergo surgery once more, thereby the patient is difficult for accepting.(4) Chinese medicine therapy: be a kind of constitutional treatment, especially oral Chinese patent medicine treatment, easy to use, whole body is carried out wholistic therapy, almost non-toxic side effect is welcome by the patient deeply.But the Chinese patent medicine kind for the treatment of hysteromyoma at present seldom, and curative effect is not ideal, presses for the medicine of determined curative effect, treatment hysteromyoma that toxic and side effects is little clinically.
Summary of the invention
The object of the present invention is to provide a kind of is the medicine of the treatment hysteromyoma made of raw material with the Chinese herbal medicine, and this medicine has no side effect, and taking convenience is evident in efficacy.
Another object of the present invention is to provide the preparation method of this medicine.
The medicine that is used for the treatment of hysteromyoma provided by the invention is the medicament of being made by the following weight proportion raw material:
Sargassum 300～400, rhizoma sparganic 300～400, Herba Duchesneae Indicae 300～400, Herba Salviae Chinensis 150～200, Radix Glycyrrhizae 40～90,
Herba Scutellariae Barbatae 150～200, Rhizoma Bistortae 150～200, Radix Codonopsis 100～160, Rhizoma Dioscoreae 40～90, Fructus Setariae Germinatus 40～90.
The above-mentioned medicine that is used for the treatment of hysteromyoma can be made said multiple dosage form on the pharmaceutics, as capsule, mixture, tablet or powder.
The above-mentioned preparation method that is used for the treatment of the medicine of hysteromyoma may further comprise the steps:
(1) get Sargassum powder and be broken into coarse powder, carry out percolation with 65～80% ethanol, medicinal residues are standby; Percolate reclaims ethanol, promptly gets Sargassum alcohol extraction concentrated solution;
(2) get Sargassum medicinal residues under nine herbal medicines such as all the other rhizoma sparganic and (1), decoct with water each 1～2 hour 2～3 times, collecting decoction filters, and filtrate is left standstill, get supernatant concentration to relative density and be about 1.15～1.23, the Sargassum alcohol extraction concentrated solution merging with under above-mentioned (1) item continues to be condensed into the thick paste that relative density is 1.30-1.35, dry, pulverize, add starch, carboxymethyl starch sodium and magnesium stearate, mix homogeneously, encapsulated, promptly make capsule of the present invention.
Medicine of the present invention has hard masses softening and resolving, blood circulation promoting and blood stasis dispelling, the effect of strengthening the body resistance.Be used for hysteromyoma (between the flesh wall, under the serous coat) syndrome of qi stagnation and blood stasis, disease is seen menostaxis, and through measuring too much, dark menses has piece, lower abdomen or distending pain of the breast etc.Usage and dosage is: oral, and a 4-6 grain, 3 times on the one, 3 menstrual cycle are a course of treatment.Generally take 1-3 the course of treatment, when menstrual phase, suspend and take.In addition, be not taken by pregnant women.Show that through the test of pesticide effectiveness medicine of the present invention has the effect of antitumor action, anti-anemia effect, the weightening finish of anti-Mouse Uterus, anti-leiomyoma of uterus, is used for the treatment of hysteromyoma, and is evident in efficacy, has no adverse reaction.
Embodiment 1
Composition of raw materials: Sargassum 343g rhizoma sparganic 343g Herba Duchesneae Indicae 343g Herba Salviae Chinensis 171g Herba Scutellariae Barbatae 171g
Rhizoma Bistortae 171g Radix Codonopsis 137g Rhizoma Dioscoreae 69g Fructus Setariae Germinatus 51g Radix Glycyrrhizae 51g
Method for making: above ten flavors, Sargassum powder is broken into coarse powder, it is closely colourless to percolate to make the solvent percolation with 75% ethanol, standby behind the percolate decompression recycling ethanol.Nine flavor and Sargassum medicinal residues such as all the other rhizoma sparganic decoct with water each 2 hours 2 times, collecting decoction filters, and filtrate was left standstill 24 hours, get supernatant concentration to relative density and be about 1.20 (60 ℃), the Sargassum percolate merging with behind the above-mentioned recovery ethanol continues to be condensed into the thick paste that relative density is 1.30-1.35 (60 ℃), dry, be ground into fine powder, add starch 60g, carboxymethyl starch sodium 15g and magnesium stearate 8g, mix homogeneously, encapsulated, promptly get capsule of the present invention.
Embodiment 2
Composition of raw materials: Sargassum 380g rhizoma sparganic 379g Herba Duchesneae Indicae 346g Herba Salviae Chinensis 162g Herba Scutellariae Barbatae 160g
Rhizoma Bistortae 175g Radix Codonopsis 140g Rhizoma Dioscoreae 80g Fructus Setariae Germinatus 60g Radix Glycyrrhizae 60g
Method for making: above ten flavors, (1) is got Sargassum powder and is broken into coarse powder, carries out percolation with 75% ethanol, and medicinal residues are standby; Percolate returns decompression and receives ethanol, promptly gets Sargassum alcohol extraction concentrated solution; (2) get Sargassum medicinal residues under nine herbal medicines such as all the other rhizoma sparganic and (1), decoct with water 3 times, each 1.5 hours, collecting decoction, filter, the filtrate high speed centrifugation, get supernatant concentration to relative density and be about 1.23 (60 ℃), with the Sargassum alcohol extraction concentrated solution merging under above-mentioned (1) item, it is the thick paste of 1.33 (60 ℃) that the continuation concentrating under reduced pressure becomes relative density, vacuum drying, be ground into fine powder, add starch 50g, carboxymethyl starch sodium 13g and magnesium stearate 10g, mix homogeneously, encapsulated, promptly get capsule of the present invention.
The present invention is to provide a kind of natural drug for the treatment of hysteromyoma, for proving its therapeutic effect and safety, the inventor uses the capsule for preparing by the method that provides in the foregoing description 1 to carry out toxicity and pharmacodynamics test, and result of study is as follows:
1, animal acute toxicity test
After the capsule mouse stomach of the present invention administration, do not find acute toxicity, mice maximum dosage-feeding on the one is 420g crude drug/kg.
2, long-term toxicity test for animals
This experimental study 3 month long term toxicities of capsule of the present invention to rat.The result shows, with three dosage of capsule of the present invention (11.2,22.4,44.8g crude drug/kg, 20 multiples, 40 times, 80 times of consumption are equivalent to respectively to be grown up) give rat continuous irrigation stomach 3 months, general situation, hematology, blood to rat is biochemical, routine urinalysis, electrocardiogram, system's dissection, organ coefficient and histopathology all do not have obvious influence, do not find toxic reaction, convalescent period does not also have the retardance toxic reaction, and prompting rat non-toxic reaction dosage is 44.8g crude drug/kg/ day.
3, Pharmacodynamic test of active extract
According to the present invention capsular effect with cure mainly, according to the principle and the method for " study of tcm new drug guide ", to capsule of the present invention carried out antitumor action, anti-anemia effect, to the influence of Mouse Uterus weightening finish, the influence of rat endocrine level and the influence of Cavia porcellus leiomyoma of uterus etc. are cured mainly relevant Pharmacodynamic test of active extract research with function.Result of study shows: the Mouse Uterus weightening finish model that (1) prepares for the method with the sc estradiol, capsule of the present invention by 2.5,5.0,10.0g crude drug/kg is to the mouse stomach administration, continuous 10 days, experimental result found that ((the 10.0g crude drug/kg) the uterus coefficient ratio model control group of mice obviously reduces (P＜0.05) to dosage group among the present invention for 5.0g crude drug/kg) and high dose group.Show that Mouse Uterus weightening finish that the present invention causes estrogen has inhibitory action to a certain degree; (2) to causing the influence of kidney invasion and attack degree after transplanting under the mice U14 cervix uteri carcinoma strain kidney capsule membrane.Experimental result shows, capsule of the present invention by 2.5,5.0,10.0g crude drug/kg is to the mouse stomach administration, continuous 15 days, compare with model group, three dosage groups are that mice kidney capsule membrane tumor bulk-growth all has obvious suppression effect (P＜0.05 or P＜0.01) to 615, and significantly ameliorate tumor is to the infringement of excess of the kidney matter.(3) to the influence of female rats endocrine level.Experimental result shows that (2.56,5.12 crude drugs/kg) the continuous ig of group gives rat after 28 days, the intravital estradiol (E of rat to low, high two dosage of the present invention
2), progesterone (P), lutropin (LH) and corticosterone blood plasma level and blank group relatively, there is no significant difference.Point out capsule of the present invention to laboratory animal estrogen and relevant endocrine hormone level do not have obvious influence.(4) anti-anemia effect: adopt the blood-letting of mouse tail blood vessel to prepare the chmice acute model of losing blood, capsule of the present invention by 2.5,5.0, the continuous ig administration of three dosage of 10.0g crude drug/kg 7 days, the result shows that middle and high dosage group has tangible rising effect to mice because of Hb and the RBC decline that acute bleeding causes.Show that the present invention has blood tonification effect to a certain degree.(5) to the effect of the Cavia porcellus leiomyoma of uterus female, that progestogen bring out: with three various dose (2.8,5.6,11.2g crude drug/kg) irritate stomach the present invention 120 days to Cavia porcellus continuously, found that three dosage groups all can suppress female to some extent, progestogen bring out leiomyoma of uterus sample hypertrophy, alleviate the weight in weightening finish uterus and smooth muscle layer thereof and pathological phenomenon such as thicken that prompting the present invention has better therapeutic effect to hysteromyoma.Above-mentioned pharmacological action may be the pharmacological basis that the present invention treats hysteromyoma.
Claims (3)
1, a kind of medicine for the treatment of hysteromyoma is characterized in that it is the medicament of being made by the following weight proportion raw material:
Sargassum 300～400, rhizoma sparganic 300～400, Herba Duchesneae Indicae 300～400, Herba Salviae Chinensis 150～200, Radix Glycyrrhizae 40～90,
Herba Scutellariae Barbatae 150～200, Rhizoma Bistortae 150～200, Radix Codonopsis 100～160, Rhizoma Dioscoreae 40～90, Fructus Setariae Germinatus 40～90.
2, the medicine of treatment hysteromyoma according to claim 1 is characterized in that described medicament is a capsule.
3, the preparation method of the medicine of the described treatment hysteromyoma of claim 2 is characterized in that may further comprise the steps:
(1) get Sargassum powder and be broken into coarse powder, carry out percolation with 65～80% ethanol, medicinal residues are standby; Percolate reclaims ethanol, promptly gets Sargassum alcohol extraction concentrated solution;
(2) get Sargassum medicinal residues under nine herbal medicines such as all the other rhizoma sparganic and (1), decoct with water each 1～2 hour 2～3 times, collecting decoction filters, and filtrate is left standstill, get supernatant concentration to relative density and be about 1.15～1.23, the Sargassum alcohol extraction concentrated solution merging with under above-mentioned (1) item continues to be condensed into the thick paste that relative density is 1.30-1.35, dry, pulverize, add starch, carboxymethyl starch sodium and magnesium stearate, mix homogeneously, encapsulated, promptly make capsule of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027218 CN1579515A (en) | 2004-05-18 | 2004-05-18 | Medicine for treating hysteromyoma and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410027218 CN1579515A (en) | 2004-05-18 | 2004-05-18 | Medicine for treating hysteromyoma and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1579515A true CN1579515A (en) | 2005-02-16 |
Family
ID=34582014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410027218 Pending CN1579515A (en) | 2004-05-18 | 2004-05-18 | Medicine for treating hysteromyoma and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1579515A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313141C (en) * | 2004-10-20 | 2007-05-02 | 成都优他制药有限责任公司 | Chinese traditional medicine composition for treating hysteromyoma and preparation and quality controlling method thereof |
| CN102631608A (en) * | 2012-05-05 | 2012-08-15 | 钱家美 | Medicament for treating myoma of uterus and preparation method of medicament |
| CN112569274A (en) * | 2020-12-24 | 2021-03-30 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | Application of bistort rhizome extract in preparation of anti-cervical cancer drugs |
-
2004
- 2004-05-18 CN CN 200410027218 patent/CN1579515A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313141C (en) * | 2004-10-20 | 2007-05-02 | 成都优他制药有限责任公司 | Chinese traditional medicine composition for treating hysteromyoma and preparation and quality controlling method thereof |
| CN102631608A (en) * | 2012-05-05 | 2012-08-15 | 钱家美 | Medicament for treating myoma of uterus and preparation method of medicament |
| CN112569274A (en) * | 2020-12-24 | 2021-03-30 | 中国科学院上海生命科学研究院湖州营养与健康产业创新中心 | Application of bistort rhizome extract in preparation of anti-cervical cancer drugs |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102716417B (en) | Traditional Chinese medicine preparation for treating gynaecopathia and preparation method of preparation | |
| CN101049484A (en) | Strong effective Chinese traditional medicine for treating lung cancer and other various cancers | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN104826016B (en) | A kind of pharmaceutical composition and its preparation method and application for treating the proliferation of mammary gland | |
| CN103893722A (en) | Traditional Chinese medicinal composition for treating solar dermatitis and preparation method thereof | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN101897821B (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as detection method thereof | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN104800720A (en) | Medicine for improving sexual desire of breeding bull and increasing yield of semen and preparation method of medicine | |
| CN1709326A (en) | Method for preparing concentrated pill for treating mammary gland proliferation disease | |
| CN118434431A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN1579515A (en) | Medicine for treating hysteromyoma and its preparation method | |
| CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
| CN102526229B (en) | Chinese medicinal composition for regulating menstruation, nourishing blood, regulating flow of qi and dissipating blood stasis and preparation method thereof | |
| CN107236050A (en) | Glycopolymers and its preparation method and application in scythian lamb rhizome | |
| CN1615978A (en) | Cassia twig and poria cocos disperse tablet and its producing method | |
| CN100484566C (en) | Chinese medicine preparation for heat-clearing, dampness-removing, diuresis and stone removing and its preparation | |
| CN102716423A (en) | Ruhesanjie capsule used for curing mammary hyperplasia diseases of women and preparation method thereof | |
| CN102579761A (en) | Application of traditional Chinese medicine beauty composition in preparation of medicament for adjusting women hormonal equilibrium | |
| CN101647901B (en) | Oral Chinese herba preparation for treating postpartum qi and blood deficiency of woman and production method thereof | |
| CN103736052A (en) | Chinese medicinal composition for assisting in decreasing blood sugar and preparation method thereof | |
| CN110575466A (en) | Composition for increasing bone mineral density and application thereof | |
| CN103071125B (en) | Traditional Chinese medicament composition for treating endometriosis and preparation method thereof | |
| CN103169887B (en) | Chinese patent medicine for improving sleep and preparation method of Chinese patent medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |